2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action

A 2-Substituted estra-1,3,5(10)-trien-3-yl sulfamates compound of formula I

• wherein
• R1 is hydrogen, C1-C8-alkyl-4 or C1-C5-acyl;
• R2 is C1-C8-alkoxy, C1-C5-alkyl or —O—CnFmHo, wherein n=1, 2, 3, 4, 5 or 6, m>1 and m+o=2n+1, wherein
• if R2 is C1-C5-alkyl, R17 is C1-C5-alkoxy;
• R6 is hydrogen;
• R7 is hydrogen, hydroxy, amino, acylamino, or
• if R6 and R7 are not hydrogen, then R17 is C1-C5-alkoxy and R6 and R7 together represent oxygen, oxime or O(C1-C5-alkyl)-oxime;
• R14 and R15 in each case is hydrogen or together a methylene group,
• R16 is hydrogen, C1-C5-alkyl, or fluorine;
• R17 is hydrogen, fluorine, or if R15 is hydrogen, R17 is a group CHXY, wherein
• X is hydrogen, fluorine, hydroxy, or C1-C4-alkyl, and
• Y is hydrogen or fluorine, wherein
• if X is fluorine, Y is hydrogen or fluorine, and
• if X is hydroxy, Y is hydrogen, or
• X and Y together are oxygen, or
• if R16 is fluorine, R17 is hydrogen or fluorine, or
• R16 and R17 together are a group ═CAB, wherein A and B, independently of one another, are hydrogen, fluorine or C1-C8-alkyl;
• and
• R18 is hydrogen atom, or methyl,
• wherein in the B- and D-rings of the steroid skeleton compound of formula I, the dotted lines represent 0, 1, or 2 double bonds, provided that when a double bond is present in the D ring, only one of R16 and R17 is present, or a pharmaceutically acceptable salt of the compound.